General
Preferred name
VALRUBICIN
Synonyms
Valstar ()
AD-32 ()
NSC-246131 ()
Valstar preservative free ()
Valrubicine ()
AD 32 ()
Valrubicina ()
P&D ID
PD014197
CAS
56124-62-0
Tags
available
drug
Approved by
FDA
First approval
1998
Drug indication
Bladder cancer
Psoriasis vulgaris
Neoplasm
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Valrubicin is an anticancer agent.
DESCRIPTION Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 ¦ÌM, respectively, and has antitumor and antiinflammatory activity.
PRICE 175
DESCRIPTION Valrubicin (AD-32) (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 ??M) and has antitumor and anti-inflammatory activity.
DESCRIPTION Valrubicin (AD-32) (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 μM) and has antitumor and anti-inflammatory activity. (TargetMol Bioactive Compound Library)
Compound Sets
18
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
JUMP-MOA Compound Set
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
36
Properties
(calculated by RDKit )
Molecular Weight
723.21
Hydrogen Bond Acceptors
13
Hydrogen Bond Donors
5
Rotatable Bonds
10
Ring Count
5
Aromatic Ring Count
2
cLogP
2.46
TPSA
215.22
Fraction CSP3
0.5
Chiral centers
6.0
Largest ring
6.0
QED
0.15
Structural alerts
1
quinone_A(370)
[!#6&!#1]=[#6]1[#6]=,:[#6][#6](=[!#6&!#1])[#6]=,:[#6]1
PAINS Family A
Custom attributes
(extracted from source data)
Target
antibiotic
PKC
TOP2A
MOA
DNA inhibitor, topoisomerase inhibitor
DNA inhibitor
Indication
bladder cancer
Pathway
Chromatin/Epigenetic
Cytoskeletal Signaling
Microbiology/virology
Anti-infection
Epigenetics
TGF-beta/Smad
Therapeutic Class
Anticancer Agents
Source data